CLDX Celldex Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CLDX

Price (delayed)

$31.12

Market cap

$2.44B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.36

Enterprise value

$2.4B

?
Relative Growth: Rel. Growth: 7
Relative Strength: Rel. Strength: 59
Relative Valuation: Rel. Valuation: 1
Relative Profitability: Rel. Profitability: 25

Celldex is a clinical stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients. Our pipeline includes antibody-based therapeutics ...

Highlights
Celldex Therapeutics's equity has soared by 57% from the previous quarter and by 9% YoY
CLDX's quick ratio is down by 39% year-on-year but it is up by 33% since the previous quarter
The debt has soared by 157% QoQ and by 62% YoY
The company's gross profit has shrunk by 97% YoY and by 82% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.celldex.com
Peers: AGEN EBS PFE NVAX

Key stats

What are the main financial stats of CLDX

CLDX stock price

How has the Celldex Therapeutics stock price performed over time
Intraday
-7.13%
1 week
-19.61%
1 month
-22.93%
1 year
28.44%
YTD
14.58%
QTD
-16.37%

Financial performance

How have Celldex Therapeutics's revenue and profit performed over time
Revenue
$158,000
Gross profit
$158,000
Operating income
-$325.83M
Net income
-$300.55M
Gross margin
100%
Net margin
-190,220.9%
The company's gross profit has shrunk by 97% YoY and by 82% QoQ
Celldex Therapeutics's revenue has plunged by 97% YoY and by 82% from the previous quarter
Celldex Therapeutics's net income has plunged by 51% YoY and by 6% from the previous quarter
Celldex Therapeutics's operating income has decreased by 39% YoY and by 5% QoQ

Price vs fundamentals

How does CLDX's price correlate with its fundamentals

Growth

What is Celldex Therapeutics's growth rate over time

Valuation

What is Celldex Therapeutics stock price valuation
P/E
N/A
P/B
3.42
P/S
15,331.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15,198.03
CLDX's EPS is down by 45% YoY and by 2.1% from the previous quarter
Celldex Therapeutics's equity has soared by 57% from the previous quarter and by 9% YoY
The P/B is 6% lower than the 5-year quarterly average of 3.9 and 3.2% lower than the last 4 quarters average of 3.8
CLDX's price to sales (P/S) is 192% higher than its last 4 quarters average of 5649.6
Celldex Therapeutics's revenue has plunged by 97% YoY and by 82% from the previous quarter

Efficiency

How efficient is Celldex Therapeutics business performance
Celldex Therapeutics's ROIC has plunged by 97% YoY and by 3.9% from the previous quarter
The ROE has plunged by 90% YoY and by 3.4% from the previous quarter
The ROA has shrunk by 82% YoY and by 2.1% QoQ

Dividends

What is CLDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLDX.

Financial health

How did Celldex Therapeutics financials performed over time
CLDX's total liabilities has surged by 83% year-on-year and by 23% since the previous quarter
Celldex Therapeutics's total assets has soared by 53% from the previous quarter and by 13% YoY
The debt is 99% lower than the equity
The debt has soared by 157% QoQ and by 62% YoY
Celldex Therapeutics's equity has soared by 57% from the previous quarter and by 9% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.